Results 281 to 290 of about 210,758 (351)

Glutathione Threshold‐Triggered Selective Breakability of Organosilica Nanocapsules

ChemCatChem, EarlyView.
Replacing tetraethoxy orthosilicate (TEOS) by tetramethoxy orthosilicate (TMOS) as silica precursor to synthesize cleavable organosilica nanocapsules enabled the effective and selective entrapment of a positively charged protein as Cytochrome C (CytC) and a much more favorable breakability and kinetics release when exposed to high glutathione (GSH ...
Andrea Mosseri, Ana Rueda‐Flores, Jose L. Hueso, Esteban Urriolabeitia, Luisa De Cola, Jesus Santamaria   +5 more
wiley   +1 more source

Personal experience with orthotopic liver transplantation. [PDF]

, 1972
Corman, J, Groth, CG, Gustafsson, A, Halgrimson, CG, Penn, I, Putnam, CW, Schroter, G, Starzl, TE   +7 more
core  

Early education of patients with chronic renal insufficiency. The Health Start Program: case study of anemic patient [ressenya bibliogràfica]

, 2002
Enrique Limón Cáceres
openalex   +1 more source

Lipid Profile Differences in HIV‐Infected Populations With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Systematic Review and Meta‐Analysis

Chronic Diseases and Translational Medicine, EarlyView.
PRISMA study flow diagram. ABSTRACT Introduction Advances in HIV management have transformed HIV into a chronic condition, resulting in improved prognosis and increased survival among people living with HIV (PLWH). Traditional risk factors for metabolic dysfunction‐associated steatotic liver disease (MASLD)—including dyslipidemia—are prevalent in PLWH.
Yovita Hartantri, Sherly Lawrensia, Steven Yulius Usman, Nenny Agustanti, Rudi Wisaksana, Nanny Natalia Mulyani Soetedjo, Bachti Alisjahbana   +6 more
wiley   +1 more source

Exercise programme for patients with chronic renal insufficiency on haemodialysis: Pilot study

, 2007
Eva Segura‐Ortí, T Momblanch, J. Martinez, A Martí-i-Monrós, Guillermo Sáez Tormo, J. F Lisón-Párraga   +5 more
openalex   +1 more source

Small‐Molecule Sarco/Endoplasmic Reticulum Ca2+‐ATPase Activators Reverse Methylglyoxal‐Induced Inhibition through Nonantioxidant Mechanisms

ChemMedChem, EarlyView.
Endoplasmic reticulum (ER) Ca2+ dysregulation drives β‐cell dysfunction under diabetic stressors like methylglyoxal, which inhibits the sarco/endoplasmic reticulum Ca2+‐ATPase (SERCA) pump through oxidative modifications. We show that synthetic SERCA activators restore pump activity after methylglyoxal‐induced damage.
Carlos Cruz‐Cortés, Silvia Micháliková, Petronela Rezbáriková, L. Michel Espinoza‐Fonseca, Jana Viskupičová   +4 more
wiley   +1 more source

Effect of early everolimus-facilitated reduction of acrolimus on efficacy and renal function in de novo liver transplant recipients: 24-month results for the North American subpopulation [PDF]

, 2017
Chapman, William C, et al,
core   +1 more source

Retrospective, Multicenter Study of Lacosamide to Treat Neonatal Seizures

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Objective Most antiseizure medications (ASMs) are prescribed off label for neonates. Lacosamide's efficacy in infants and availability in intravenous formulation suggest potential utility for neonates. We evaluated the safety and efficacy of lacosamide for neonatal seizures. Methods This 10‐center, retrospective study of neonates with seizures
Alexandra Santana Almansa, Jessica R. Landers, Nicholas S. Abend, Giulia M. Benedetti, Catherine J. Chu, Andrew T. Knox, Shavonne Massey, Steffany Moen, Andrea C. Pardo, Arnold Sansevere, Renée A. Shellhaas, Cameron Thomas, Tammy Tsuchida, Sonya Wang, Bo Zhang, Janet S. Soul   +15 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R. Srinivas, Randall Kaye   +7 more
wiley   +1 more source

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG‐055009, a novel thyroid hormone receptor beta (THR‐β) agonist for metabolic dysfunction‐associated steatohepatitis (MASH), in healthy participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract ALG–055009 is an oral thyroid hormone receptor beta (THR‐β) agonist being evaluated for treating metabolic dysfunction–associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG‐055009 and bioavailability/food effect.
Hakim Charfi, Benedetta Massetto, Megan Fitzgerald, Kha Le, Stanley Wang, Ifong Kan‐Eng, Meenakshi Venkatraman, Naqvi Mohammad, Lawrence Blatt, Tse‐I Lin, Sushmita M. Chanda, John Fry   +11 more
wiley   +1 more source